Good News About GLP-1 Drugs and Cardiovascular Health

A popular non-insulin injectable drug that long ago met the FDA cardiovascular safety test can now claim a cardiovascular benefit.

Weighing the Benefits of a Bariatric Procedure

When diet and lifestyle changes to combat obesity don’t work, surgical approaches and new generation devices can, but they all require a lifelong commitment.

Janssen’s SGLT-2 Drugs and Risk of Amputations: What Happened, and What’s Next?

The European regulators have applied their amputation risk warning to all Janssen products in the SGLT-2 inhibitor class. But FDA has yet to require its risk warning for comparable products from Eli Lilly and AstraZeneca.

New CDC Diabetes Stats: Type 2 Still an Epidemic, But Rate of Growth Is Slowing

The CDC 2017 report on the prevalence of diabetes shows more Americans have diabetes or prediabetes than shown in the CDC’s 2014 report. But there is still a bit of good news.

Keeping Diabetic Eye Disease In Check

Here’s our reminder that you need to visit your eye doctor regularly to check for signs of diabetic retinopathy. We’re backing this reminder with information from the American Diabetes Association on proper vision care, and we have a new technology to tell you about.

Having A Look At The American Diabetes Association’s 2017 Clinical Practice Update

Many T2D’s treat almost exclusively with the family doctor. The American Diabetes Association publishes an annual update of its clinical practice guidelines for primary care doctors, and we’ve looked at what’s new for 2017.

Debating Fatness and Fitness

Body Mass Index, not bodily dimension, is what really matters.

FDA To Require Prominent Amputation Risk Warning for Canagliflozin SGLT-2 Inhibitors

Post-market clinical trials of the Type 2 medication canagliflozin to assess cardiovascular and renal risks have affirmed a suspected link to leg and toe loss, warranting a step up in FDA’s warning protocol. Action follows similar move by Canada and a lower level 2016 FDA advisory about amputation risk.

Sponsor

Sponsor